Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 239

1.

The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.

Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH.

J Mol Cell Cardiol. 2004 Aug;37(2):449-71. Review.

PMID:
15276015
[PubMed - indexed for MEDLINE]
2.

Cardiac regulation by phosphoinositide 3-kinases and PTEN.

Oudit GY, Penninger JM.

Cardiovasc Res. 2009 May 1;82(2):250-60. doi: 10.1093/cvr/cvp014. Epub 2009 Jan 15. Review.

PMID:
19147653
[PubMed - indexed for MEDLINE]
Free Article
3.

Signalling through Class I PI3Ks in mammalian cells.

Hawkins PT, Anderson KE, Davidson K, Stephens LR.

Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62. Review.

PMID:
17052169
[PubMed - indexed for MEDLINE]
4.

Targeting phosphoinositide 3-kinase: moving towards therapy.

Marone R, Cmiljanovic V, Giese B, Wymann MP.

Biochim Biophys Acta. 2008 Jan;1784(1):159-85. Epub 2007 Oct 12. Review.

PMID:
17997386
[PubMed - indexed for MEDLINE]
5.

Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors.

Freeburn RW, Wright KL, Burgess SJ, Astoul E, Cantrell DA, Ward SG.

J Immunol. 2002 Nov 15;169(10):5441-50.

PMID:
12421919
[PubMed - indexed for MEDLINE]
Free Article
6.

The biology and clinical relevance of the PTEN tumor suppressor pathway.

Sansal I, Sellers WR.

J Clin Oncol. 2004 Jul 15;22(14):2954-63. Review.

PMID:
15254063
[PubMed - indexed for MEDLINE]
7.

Phosphoinositide 3-kinase signalling in the vascular system.

Morello F, Perino A, Hirsch E.

Cardiovasc Res. 2009 May 1;82(2):261-71. doi: 10.1093/cvr/cvn325. Epub 2008 Nov 26. Review.

PMID:
19038971
[PubMed - indexed for MEDLINE]
Free Article
8.

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.

Steelman LS, Bertrand FE, McCubrey JA.

Expert Opin Ther Targets. 2004 Dec;8(6):537-50. Review.

PMID:
15584861
[PubMed - indexed for MEDLINE]
9.

Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.

Downes CP, Bennett D, McConnachie G, Leslie NR, Pass I, MacPhee C, Patel L, Gray A.

Biochem Soc Trans. 2001 Nov;29(Pt 6):846-51. Review.

PMID:
11709086
[PubMed - indexed for MEDLINE]
10.

Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways.

Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM.

Cell. 2002 Sep 20;110(6):737-49.

PMID:
12297047
[PubMed - indexed for MEDLINE]
11.

Phosphoinositide 3-kinase gamma: kinase-dependent and -independent activities in cardiovascular function and disease.

Alloatti G, Montrucchio G, Lembo G, Hirsch E.

Biochem Soc Trans. 2004 Apr;32(Pt 2):383-6. Review.

PMID:
15046613
[PubMed - indexed for MEDLINE]
12.

PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.

Besson A, Robbins SM, Yong VW.

Eur J Biochem. 1999 Aug;263(3):605-11. Review.

PMID:
10469123
[PubMed - indexed for MEDLINE]
Free Article
13.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
[PubMed - indexed for MEDLINE]
14.

PTEN: life as a tumor suppressor.

Simpson L, Parsons R.

Exp Cell Res. 2001 Mar 10;264(1):29-41. Review.

PMID:
11237521
[PubMed - indexed for MEDLINE]
15.

PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac.

Kim JS, Peng X, De PK, Geahlen RL, Durden DL.

Blood. 2002 Jan 15;99(2):694-7.

PMID:
11781256
[PubMed - indexed for MEDLINE]
Free Article
16.

Lipid phosphatases in the regulation of T cell activation: living up to their PTEN-tial.

Seminario MC, Wange RL.

Immunol Rev. 2003 Apr;192:80-97. Review.

PMID:
12670397
[PubMed - indexed for MEDLINE]
17.
18.

Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.

Oudit GY, Kassiri Z, Zhou J, Liu QC, Liu PP, Backx PH, Dawood F, Crackower MA, Scholey JW, Penninger JM.

Cardiovasc Res. 2008 Jun 1;78(3):505-14. doi: 10.1093/cvr/cvn041. Epub 2008 Feb 15.

PMID:
18281373
[PubMed - indexed for MEDLINE]
Free Article
19.

Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.

Pirola L, Zvelebil MJ, Bulgarelli-Leva G, Van Obberghen E, Waterfield MD, Wymann MP.

J Biol Chem. 2001 Jun 15;276(24):21544-54. Epub 2001 Feb 13.

PMID:
11278889
[PubMed - indexed for MEDLINE]
Free Article
20.

Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling.

Sun H, Kerfant BG, Zhao D, Trivieri MG, Oudit GY, Penninger JM, Backx PH.

Circ Res. 2006 Jun 9;98(11):1390-7. Epub 2006 Apr 20.

PMID:
16627784
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk